Altered proteolytic events in experimental autoimmune encephalomyelitis discovered by iTRAQ shotgun proteomics analysis of spinal cord by Jain, Mohit Raja et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Proteome Science
Open Access Research
Altered proteolytic events in experimental autoimmune 
encephalomyelitis discovered by iTRAQ shotgun proteomics 
analysis of spinal cord
Mohit Raja Jain†1, Shengjie Bian†1, Tong Liu†1, Jun Hu1, Stella Elkabes2 and 
Hong Li*1
Address: 1Center for Advanced Proteomics Research and Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School 
Cancer Research Center, Newark, NJ 07103, USA and 2Department of Neurology and Neuroscience, UMDNJ-New Jersey Medical School, Newark, 
NJ 07103, USA
Email: Mohit Raja Jain - jainmr@umdnj.edu; Shengjie Bian - biansh@umdnj.edu; Tong Liu - linto@umdnj.edu; Jun Hu - huju@umdnj.edu; 
Stella Elkabes - elkabest@umdnj.edu; Hong Li* - liho2@umdnj.edu
* Corresponding author    †Equal contributors
Abstract
Background:  Abnormal activation of protease activities during experimental autoimmune
encephalomyelitis (EAE) in rats, a rodent model of multiple sclerosis, have been implicated in either
the direct destruction of myelin components or the intracellular signal transduction pathways that
lead to lymphocyte infiltration, oligodendrocyte destruction, neuronal dysfunctions and axonal
degeneration. The identification of changes in regulated proteolytic events during EAE is crucial for
uncovering activated proteases that may underline the pathological features such as inflammation
and demyelination. We searched for either non-tryptic or semi-tryptic peptides from a previous
shotgun proteomics study using isobaric tags for relative and absolute quantification (iTRAQ) to
compare the proteomes of normal and EAE rat lumbar spinal cords.
Results: We discovered that several proteins, such as α1-macroglobulin, a protease inhibitor, α1B-
glycoprotein, β2-microglobulin, neurofilament light polypeptide and sulfated glycoprotein 1 had
non-tryptic peptide iTRAQ ratios that were substantially different from the overall protein iTRAQ
ratios, suggesting that such peptides may be markers for the proteolytic products generated by the
protease(s) altered during EAE. Indeed, subsequent Western blotting confirmed the dysregulation
of specific protein cleavages in EAE tissues. Additional proteolytic changes in α2-macroglobulin,
another protease inhibitor similar to α1-macroglobulin was also observed.
Conclusion:  The results from this study revealed changes among both neuronal protein
processing and endogenous proteolysis modulators in EAE animals. This information may provide
a rationale for protease inhibitor-based therapeutic interventions for multiple sclerosis.
Background
Proteases and peptidases are important regulators that
govern many cellular functions [1]. Some protease activi-
ties are manifested globally, e.g. during protein turnover
in lysosomes and proteasomes. Other proteases are acti-
vated only within particular defined contexts, serving spe-
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cific signal transduction and other regulatory functions.
Well-known examples include the caspase cascade during
apoptosis, the coagulation cascade during clot formation
and the classical and alternative complement innate
immune systems for pathogen clearance. More recently,
regulated proteolysis events have been implicated in
numerous disease-related processes, including calpain
activation following excitotoxicity in neuronal cells [2],
matrix metalloprotease (MMP) modulation during cancer
metastasis and multiple sclerosis [3], and the contribution
of rennin and angiotensin converting enzyme to regulate
blood pressure and cardiovascular function [4]. Under-
standing how protease activities are regulated is important
both for discerning basic biological mechanisms and for
developing therapies that can regulate pathological pro-
tease activities.
Quantitative proteomics techniques have been developed
to uncover regulated proteolysis events (i.e. the identifica-
tion of the cleavage sites within targeted proteins) and
possibly identify the responsible protease(s). These meth-
ods can be broadly divided into following categories: 1)
quantification of changes among selective proteases; 2)
quantification of known protease substrates; 3) selective
quantification of protein N-termini. For example, Cravatt
et al. pioneered an activity-based proteomics technique to
use selective inhibitors for affinity enrichment and quan-
tification of proteases [5]. Overall et al. developed several
strategies to quantify changes in known or putative pro-
tease substrates in cells and tissues expressing different
levels of MMPs with great success [6,7]. In particular, their
work has utilized the iTRAQ technique for the identifica-
tion of protease substrates and determination of proteo-
lytic sites [8]. In line with the general theme that sub-
proteome analyses are usually more sensitive than global
proteomic studies for specific biological objectives. Van
Damme et al. refined a technique called combined frac-
tional diagonal chromatography to separate N-terminal
peptides from their internal tryptic counterparts for more
sensitive degradomic analysis [9]. Recently, Wells group
demonstrated an elegant technique for global identifica-
tion of proteolytic cleavage sites within proteins in apop-
totic cells by specific labeling of protein N-termini [10].
After, selectively biotinylating the α-amines of N-termini
of peptides (including neo N-termini produced during
apoptosis) with subtiligase, derivatized tryptic peptides
were enriched on an avidin media, and the sites of prote-
olytic cleavage were identified by LC-MS/MS. All of these
specialized methods and experimental designs have been
proven effective for revealing different aspects of the
degradome. Given the complexities involved in biological
systems, however, it may not always be possible to pre-
dict, whether altered proteolytic events are important for
a study in which proteomics analysis is needed. Because of
this, there are many quantitative data that have already
been obtained for expression proteomics studies could
contain valuable information on altered proteolytic
events that are critical for the underlying biological sce-
narios. In this report, we demonstrate a simple method to
uncover regulated proteolytic events from a quantitative
shotgun proteomics dataset obtained using the iTRAQ
technique [11]. The validity of our current approach is
based on the assumptions that: 1) regulated proteolytic
activities are typically non-tryptic, so the resulting pep-
tides would be either semi- or non-tryptic and 2) the
iTRAQ expression ratios for these peptides are different
from those of the tryptic peptides derived from the same
protein. Obviously, these assumptions do not apply to the
targets of those proteases whose substrate specificities
overlap with trypsin.
The model systems used in the present study were the spi-
nal cords isolated from rats suffering from EAE, a well-
characterized animal model of multiple sclerosis [4,11].
This human neurodegenerative autoimmune disease is
characterized by inflammation, demyelination in the cen-
tral nervous system (CNS), axonal damage and neuronal
loss leading to neurological deficits such as paresis and
paralysis. Since the mechanisms underlying the damages
to CNS cells in this disease remain elusive, we have previ-
ously utilized the iTRAQ technology to define differen-
tially expressed and post-translationally modified
proteins during acute EAE in the Lewis rat lumbar spinal
cord, the region most affected in this model [11,12]. Ele-
vated levels of proteases such as MMPs have previously
been suggested to play a role in mediating EAE pathology
[4], and functional inhibition of selective MMP activities
has been shown to alleviate EAE symptoms [4]. Interest-
ingly, inhibition of MMP-2 and MMP-12 made some ani-
mals more susceptible to EAE [13], suggesting that the
proteolytic activity in EAE is rather complex and providing
a rationale for further analysis of the EAE degradome. In
this study, we were able to identify changes in regulated
proteolysis events in EAE via searching for non-tryptic and
semi-tryptic peptides. By comparing the iTRAQ expression
ratios of the semi and non-tryptic fragments with their
putative protein expression ratios averaged from the
iTRAQ ratio of all tryptic peptide, we were able to uncover
changes in selective CNS proteins and endogenous pro-
tease inhibitors. These results were in accord with known
protease dysregulations reported in tissues of both EAE
animals and multiple sclerosis patients. This additional
information clearly complements differential expression
data commonly sought after by those performing shotgun
proteomics studies and it can be obtained with relatively
little additional effort and cost, thus improving proteomic
research productivity.Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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Results
Identification of Differentially Cleaved Protein Products
In our previous study, we reported the identification of 41
differentially expressed proteins [11] and changes in cit-
rullination, methylation and phosphorylation of various
proteins [12] in the spinal cord of EAE animals. To our
surprise, we also discovered the increased levels of a dis-
tinct proteolytic fragment (~50 kDa) of moesin in EAE
spinal cords, following Western blotting validation analy-
sis of iTRAQ quantitation results [11], suggesting that
there may be other proteolytic products present in EAE
animal tissues. In the current study, we examined proteins
that were differentially cleaved in EAE animals. We iden-
tified 197 semi-tryptic or non-tryptic peptides belonging
to 104 proteins (see Additional file 1). Among these, we
found seven proteolytic products whose levels were signif-
icantly altered in EAE compared to control animals,
although the corresponding total protein levels were not
changed to the same degrees (Table 1, see Additional files
2 and 3). For example, a semi-tryptic peptide
(437GFCEVCK443) from sulfated glycoprotein 1, produced
from N-terminal non tryptic cleavage between G436 and
G437, was found to be dramatically increased in EAE tis-
sues and had an iTRAQ ratio of 4.5 (Fig. 1A). However, its
total protein level deduced from all the tryptic peptides
(see Additional file 2) observed for this protein was
altered to a lesser extent (EAE/control ratio of 1.9, Table
1), as demonstrated by the iTRAQ reporter ion regions for
a representative tryptic peptide 68TVVTEAGNLLK78 for this
protein (Table 1 and Fig. 1B). Similarly, a semi-tryptic
peptide  807FLELTLPYSVVR818  from  α1-macroglobulin
(α1M) (Fig. 1C) was found to be significantly elevated
with an iTRAQ ratio of 5.9 in the EAE tissues; however, the
total α1M protein level was increased with an iTRAQ ratio
of 2.8 (Table 1 and Fig. 1D). Likewise, another semi-tryp-
tic peptide 84ILAHTEFTPTETDVYACR101  from  β2-
microgloublin was found to be increased with an iTRAQ
ratio of 3.1 in the EAE tissue as compared to an iTRAQ
Table 1: Altered non-tryptic cleaved peptides in EAE rat spinal cord
Protein Swiss-Prot 
Accession 
Number
Peptidea Observed 
Mass (m/z)
Error (ppm) Peptide 
Ratiob ± SD
p-Value Protein 
Ratio (N)c
Sequence 
Coverage 
(%)
α1B-
glycoprotein
Q9EPH1|A1B
G
GPGNA-
21LWLDSGSEP
ELR32-AEPQS
1545.743 38 4.3 ± 1.2 0.02 3.3 (5) 6
α1-
Macroglobulin
Q63041|A1M VFQPF-
807FLELTLPYS
VVR818-GEAFI
1580.917 0 5.9 ± 1.6 0.03 2.8 (19) 13
β2-
Microglobulin
P07151|B2MG DWSFY-
83ILAHTEFTPT
ETDVYACR101
-VKHVT
2257.067 4 3.1 ± 0.8 0.02 2.7 (2) 26
Neurofilament 
light 
polypeptide
P19527|NFL AFPAY-
443YTSHVQEE
QSEVEETIEAT
K463-AEEAK
2625.292 6 2.2 ± 0.6 0.05 0.9 (75) 56
Phospho 
glucomutase-1
P38652|PGM1 KFKPF-
184TVEIVDSVE
AYATMLR200-
NIFDF
1941.006 -3 1.6 ± 0.1 0.01 1.1 (6) 17
Sulfated 
glycoprotein 1
P10960|SAP QPKAN-
194EDVCQDC
MK202-LVTDI
1450.59 11 2.4 ± 0.2 0.00 1.9 (16) 19
Sulfated 
glycoprotein 1
P10960|SAP PQKNG-
437GFCEVCK44
3-KLVIY
1165.508 -3 4.5 ± 0.7 0.00 1.9 (16) 19
a Sequences bracketed by amino acid numbers are the semi-tryptic peptides discovered experimentally. Five amino acids before and after the semi-
tryptic peptides are shown to indicate the non tryptic cleavage sites.
b iTRAQ Ratio: EAE/Control
c Total number of peptides identified for respective protein (see Additional file 2)Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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ratio of 2.7 in total β2-microgloublin protein level (Table
1). Interestingly, the semi-tryptic peptides from both neu-
rofilament light polypeptide
(443YTSHVQEEQSEVEETIEATK463) and phosphogluco-
mutase-1 (184TVEIVDSVEAYATMLR200) were higher
(iTRAQ ratios of 2.2 and 1.6 respectively) in EAE tissues.
However, no significant changes were observed in their
protein levels (iTRAQ ratios of 0.9 and 1.1 respectively,
Table 1) in EAE tissues.
Corroboration of iTRAQ analysis by Western Blot
In this study, we observed that several proteins previously
implicated in EAE etiology were differentially processed. A
highly specific antibody for rat α1M is not commercially
available for validation. However, rat α-macroglobulins 1
and 2 (α2M) are similar in their amino acid sequence
(56% of sequence homology, see Additional file 4) and
have been suggested to have comparable three-dimen-
sional structures and function [14]. We tested whether
MS/MS spectra of representative semi-tryptic and tryptic peptides Figure 1
MS/MS spectra of representative semi-tryptic and tryptic peptides. iTRAQ reporter ion region and peptide sequenc-
ing region of the MS/MS spectrum for semitryptic peptides derived from (A) sulfated glycoprotein 1 (437–443) and (C) α1-mac-
roglobulin (807–818). Representative tryptic peptides changes are shown for (B) sulfated glycoprotein 1(232–241) and (D) α1-
macroglobulin (1187–1201). Peptide sequences were deduced from the MS/MS spectra based on the observation of continuous 
series of either N-terminal (b-series) or C-terminal (y-series) ions. The peak areas of iTRAQ quantification (shown in insets of 
A, B, C, D) ions, m/z 114–117 were used to measure the relative abundance of individual peptides.Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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α2M may also be similarly processed as with α1M in EAE
by analyzing the presence of both breakdown products
using an antibody against α2M (Fig. 2A). Interestingly, the
levels of both intact α2M (~165 kDa) and a proteolytic
product (~80 kDa) were elevated in the EAE tissues than
the controls (Fig. 2A). Another α2M proteolytic product
(~60 kDa) levels were also found to be increased in the
EAE tissues (Fig. 2A). Using a longer exposure of the West-
ern blotting film, more proteolytic fragments can be
observed in the EAE tissues (see Additional file 5). We fur-
ther probed for the presence of proteolytic products from
other proteins for which the specific antibodies are com-
mercially available. In the case of β2-microglobulin,
which was increased in the EAE tissues (iTRAQ ratio of
2.7, Table 1), we found that the levels of both the intact
protein as well as its proteolytic fragment were dramati-
cally increased in the EAE tissues by Western blotting (Fig.
2B), corroborating the observations made from the
iTRAQ experiment. We also probed for the presence of
proteolytic products of sulfated glycoprotein 1. The levels
of the intact protein (~62 kDa) were found to be increased
in the EAE tissues (see Additional file 5), corroborating
iTRAQ results (Table 1). However, we could not find the
presence of its proteolytic products, which may be indica-
tive of either rapid degradation of the proteolytic products
or changes in the epitopes for the antibody used. The neu-
rofilament light polypeptide was found unchanged in the
EAE tissues by iTRAQ analysis (Table 1). Using an anti-
neurofilament light polypeptide antibody, we confirmed
that intact neurofilament light polypeptide (~68 kDa) was
not changed in the EAE tissues (see Additional file 5);
however, by comparison, a putative proteolytic product
(~11 kDa) was increased by ~10% in the EAE tissues (see
Additional file 5).
Discussion
There are many techniques for the analysis of the degra-
dome. Although the methods employed here do not
incorporate enrichment techniques, we were able to iden-
tify cleaved proteins. Although we assumed only non-
tryptic fragments as markers for cleaved proteins in the
spinal cord of rats affected by EAE, there are proteases –
especially in the serine protease family – whose substrate
cleavage specificities may overlap with trypsin. In princi-
ple, such cleavages may also be identified by iTRAQ anal-
ysis, but it is difficult to distinguish endogenous cleavages
from tryptic cleavages of extracted proteins. Under such
circumstances, the techniques developed by McDonald et
al [15] and Ji et al [16] to first block the protein N-termini
prior to tryptic digestion and enrichment of the neo-N-ter-
mini should be used to discover the proteolytically mod-
ulated proteins. Overall, we have observed nearly 200 non
or semi-tryptic events in over 100 proteins. It is likely that
significantly more such events could be detected with
focused sub-proteomic analysis of the degradomes, using
the approaches elegantly described by Wells [10], Van
Damme [9] and others. However, since most expression
proteomics experiments have been conducted without the
Western blot validation of select protein cleavages Figure 2
Western blot validation of select protein cleavages. (A) α2-macroglobulin, (B) β2-microglobulin from both control (C1, 
C2, C3) and EAE (E1, E2, E3) animals. (C) GAPDH was used to determine the equal loading of proteins for all the samples.Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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enrichment of the protein N-termini, it is important to be
able to extract differential proteolytic signals from such
studies in addition to protein expression information,
considering the significant amount of resources devoted
for such experiments. We have demonstrated here that it
is possible to obtain such information with bioinformatic
data reprocessing. The existence of differential proteolysis
in the expression proteomic datasets may provide a
rationale for subsequently more focused degradomic
studies.
EAE is an established animal model for studying cellular
pathways leading to demyelination, axonal damage, lym-
phocyte infiltration of the CNS, and other processes that
occur in CNS of multiple sclerosis patients [17-19]. Our
previous iTRAQ analysis of the spinal cord in acute EAE
revealed 41 differentially expressed proteins, including
complement C3, α2M, ceruloplasmin, and other acute
phase proteins commonly associated with systematic
inflammation [11]. During different stages of multiple
sclerosis and EAE, aberrant proteolytic processes have
been reported to be involved in axonal damage, oli-
godendrocyte apoptosis, demyelination, pro-inflamma-
tory cytokine activation, epitope spreading, T cell and
macrophage activation, and damage to the blood brain
barrier [4]. Although some of these proteolytic events
involve tissue triage and broader damage, under most cir-
cumstances, the implicated proteolytic events involve lim-
ited cleavages at specific peptide bonds [4], suggesting the
existence of regulated proteolytic events. The dysregula-
tion of proteolysis in EAE pathology may be dependent
on protease levels, localization, activation and endog-
enous inhibitor concentrations [4]. For example, MMPs
including MMP-9, 2, 14, 3, 7, 12, 8 have been reported to
be elevated at different stages of multiple sclerosis [4,13],
and they are important promoters of immune cell extrava-
sation into the CNS via the opening of the blood brain
barrier due to their unique ability to facilitate fibronolysis
[20]. In addition to MMPs and their inhibitors, serine pro-
teases, such as tissue plasminogen activator (tPA), uroki-
nase plasminogen activator, thrombin, elastase, tissue
kallikreins and their inhibitors have also been reported to
be activated in various multiple sclerosis patients and ani-
mal models [4].
Among the proteins that were found to have increased
proteolytic cleavage products is α1M, also known as preg-
nancy zone protein. It is a widely expressed plasma glyco-
protein protease inhibitor that belongs to the α2M family
[21]. These protease inhibitors are synthesized in the liver
and form dimeric and tetrameric complexes in vivo. α1M
has been shown to be cleaved by both MMP-2 and MMP-
9, and it is capable of inhibiting mast cell tryptase, tPA,
chymotrypsin and snake venom metalloprotease [22,23].
These protease inhibitors function by forming thiol esters
with protease side chains following their cleavage by the
proteases with a "bait region" and inhibiting protease
activity towards other high molecular weight substrates
[24]. α1M has been shown to selectively inhibit T-cell acti-
vation and IL-2 secretion [25] and also binds to both TGF-
β1 and TGF-β2 [26], inhibiting their association with their
cell surface receptors, which may be protective for EAE
animals [25]. Given the functional significance of α1M,
the observation of the increase of its cleavage products in
EAE suggests that it may play a protective role by dampen-
ing the effect of harmful proteases. Similarly, α2M has
been shown by Western blot analysis to be cleaved
(increase in an 80 kDa fragment) in EAE spinal cords. Our
previous studies have shown a significant increase (iTRAQ
ratio of 2.3) in α2M protein levels [11]. α2M can be pro-
duced by activated macrophages, has been shown to
attenuate EAE symptoms when administered exoge-
nously, and may exert its beneficial effects by either neu-
tralizing proteinases involved in tissue damage or directly
interfering with antigen recognition due to its ability to
bind myelin basic protein [24]. EAE is an inflammatory
autoimmune condition in affected animals. It is interest-
ing to see that several immune system proteins were dif-
ferentially cleaved in EAE. β2-microglobulin is part of
MHC class I molecule that is important for antigen pres-
entation [27]. Neurofilament light polypeptide has been
reported to be degraded in EAE animals putatively by cal-
pain [28] and possibly the result of increased oxidative
stress during EAE [29]. Based on our proteomics study, it
appears that proteins related to neuroinflammation, neu-
roregeneration and axonal integrity may proteolytically
processed in EAE. Further studies are needed to determine
the functional significance of these cleaved proteins.
Conclusion
Proteolysis is an important means of post-translational
regulation of neuronal cell function; its dysregulation may
underlie the pathology of EAE and multiple sclerosis.
Many of the implicated proteases are important regulator
of cytokines and chemokines [4]. Changes in different
protease inhibitors discovered in this study, like α1M and
α2M (Table 1) and their proteolytic fragments have been
reported in recent proteomics searches for clinical
biomarkers. For example, a cleaved product of cystatin C,
an inhibitor of cysteine proteases has been reported as a
potential biomarker in the cerebrospinal fluid of multiple
sclerosis patients [30], although the validity of this pep-
tide as disease biomarker has recently been challenged by
another study [31]. The results from our current study
revealed changes among both neuronal protein process-
ing and endogenous proteolysis modulators. This infor-
mation may provide a rationale for further studies to
develop protease inhibitor-based therapeutic interven-
tions for demyelinating diseases and multiple sclerosis.Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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Methods
Induction of EAE
Two month-old Lewis rats were immunized with myelin
basic protein (MBP) emulsified in complete Freund's
adjuvant (CFA) or CFA-containing vehicle according to
Nicot et al [32]. Rats were maintained in a standard 12 h
light/dark cycle and had free access to water and food
based on approved IACUC protocols. EAE clinical symp-
toms were scored as follows: 1, tail weakness; 2, hind limb
weakness; 3, hind limb paralysis; 4, quadriplegia; and 5,
moribund. For this study, lumbar spinal cords (region
most affected by EAE) were harvested when EAE-induced
rats exhibited hind limb paralysis (clinical score 3). The
dissected lumbar spinal cords were immediately frozen on
dry ice and stored at -80°C until further use.
Protein extraction and iTRAQ labeling
For iTRAQ analysis, detailed methods have been
described previously [11]. Briefly, lumbar spinal cords
obtained from two CFA-treated controls and two rats
affected by EAE were used. Fifteen milligrams of the spinal
cord tissues were homogenized in 300 μl of a lysis buffer
consisting of 25 mM triethylammonium bicarbonate, 20
mM sodium carbonate and 2 μl of protease inhibitor
cocktail (Sigma, St Louis, MO, USA). The supernatant was
cleared by centrifugation at 19,000 × g for 30 min, and the
pH was adjusted to 8.0 with 0.1 M HEPES. The iTRAQ
labeling procedures were performed according to the
manufacturer's instructions (Applied Biosystems (ABI),
Foster City, CA). Ninety micrograms of soluble proteins
from each sample was reduced by the addition of 2 μl of
the reducing agent, tris (2-carboxyethyl) phosphine
hydrochloride (TCEP) and incubated at 60°C for 1 h.
Reduced cysteines were then alkylated with the addition
of 1 μl of 200 mM methyl methanethiosulfonate (MMTS)
and incubated at room temperature for 10 min. To initiate
tryptic digestion, 10 μg of trypsin (Promega Corporation,
Madison, WI USA) was added to each of the four samples
and incubated at 37°C overnight. The resulting peptides
were labeled with the appropriate iTRAQ reagents. Sam-
ples derived from two different control spinal cords were
labeled with iTRAQ tags 114 and 115, whereas samples
obtained from two independent EAE spinal cords were
labeled with tags 116 and 117. The labeled samples were
then mixed together and fractionated via a strong cation
exchange chromatography (SCX) on a BioCAD™ Per-
fusion Chromatography System (ABI), equipped with a
polysulfoethyl A column (4.6 mm × 200 mm, 5 μm, 300
A°, Poly LC Inc., Columbia, MD, USA) and an upstream
guard column (4.0 mm × 10 mm, Poly LC). The peptide
mixture was separated with a gradient consisting of
mobile phase A, containing 10 mM KH2PO4 and 20% ace-
tonitrile (ACN) (pH 3.0), and mobile phase B, consisting
of 600 mM KCl, 10 mM KH2PO4 and 20% ACN (pH 3.0).
Labeled peptides were eluted with a 40-min linear gradi-
ent from 0 to 50% B, followed by another 10 min from 50
to 100% B. Two-minute fractions were dried via speed-vac
and desalted via PepClean™ C18 spin columns (Pierce,
Rockford, IL, USA). Desalted peptides were further frac-
tionated on an Ultimate™ Chromatography System
equipped with a Probot matrix-assisted laser desorption
ionization (MALDI) spotting device (Dionex, Sunnyvale,
CA, USA). Peptides were first captured onto a reversed
phase trapping column (0.3 mm × 5.0 mm) and then
resolved on a 0.1 mm × 150 mm capillary PepMap col-
umn (3 um, 100 A°, C18, Dionex), with a 70-min gradient
of solvent A (5% ACN, 0.1% trifluoroacetic acid, TFA) and
solvent B (95% CAN and 0.1% TFA): 0–4 min, from 5 to
8% B; at 34 min, to 18% B; at 57 min, to 35% B and at 64
min, to 95% B. The HPLC eluent was mixed in a 1:3 ratio
with a MALDI matrix solution (7 mg/ml alpha-cyano-4-
hydroxycinnamic acid, in 60% ACN, 5 mM of ammo-
nium monobasic phosphate and the internal mass cali-
brants, 50 fmol/μl each of GFP and ACTH, 18–39)
through a 30 nl mixing tee and spotted onto the MALDI
plates in an 18×18 spot array format. The peptides were
analyzed on a 4700 Proteomics Analyzer MALDI-TOF-
TOF tandem mass spectrometer (ABI) in a data-depend-
ent fashion using a job-wide interpretation method. MS
spectra (m/z 800-3,600) were acquired in positive ion
reflector mode with internal mass calibration. A maxi-
mum of the ten most intense ions (S/N > 50) per spot
were selected for subsequent MS/MS analysis in 1 k eV
mode. Each spectrum was averaged over 4,000 laser shots.
Protein database search and bioinformatics
For automated peptide identification, ProteinPilot soft-
ware (v. 2.0.1, Revision 67128, ABI) was used to process
the tandem mass spectra to generate the peak lists for
database search, using default parameters optimized by
the manufacturer. For peptide identification, ProteinPilot
uses both MS and MS/MS mass error tolerance based on
established mass accuracy performance of the 4700 Pro-
teomics Analyzer MALDI-TOF-TOF tandem mass spec-
trometer (ABI). The peak list was submitted for a
"thorough" search against the rat sequences in the Uni-
ProtKB/Swiss-Prot v54.8 database (Release date Feb 05,
2008, 349,480 sequence entries) using the Paragon algo-
rithm [33] with default parameters. The following search
parameters were used: trypsin as a digesting agent, iTRAQ-
labeled N-termini and lysines and MMTS-labeled
cysteines were set as fixed modifications; oxidized
methionines and iTRAQ-labeled tyrosines were set as var-
iable modifications. The Paragon algorithm automatically
search for semi- and non-tryptic peptides in addition to
tryptic ones. The semi-tryptic peptides identified with
confidence interval (CI) values ≥ 99% and MS measure-
ment error ≤ 50 ppm were used for the degradome analy-
sis. To reduce the probability of false identification, we
chose to report only proteins containing at least two pep-Proteome Science 2009, 7:25 http://www.proteomesci.com/content/7/1/25
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tides with confidence values ≥ 95%. Semi-tryptic peptides
were also verified by manual examination of the spectra
(see Additional file 3). The false discovery rate (FDR) was
estimated by researching the spectra against a target decoy
database containing both forward and reverse rat protein
entries [34]. The FDR for this study was estimated to be
5.0%. Relative quantification of peptides in each sample
was calculated from the areas under the peaks at m/z
114.1, 115.1, 116.1 and 117.1. The calculated peak area
ratios were corrected for overlapping isotopic contribu-
tions as per manufacturer's instructions. If peptides iden-
tified are common to different isoforms of related
proteins, Pro Group™ Algorithm (ABI), a component
within the ProteinPilot software, was used to calculate
protein ratios using only iTRAQ ratios from the peptides
that were distinct to each isoform and thus provide iso-
form-specific quantitation. P-values were derived via the
1-tailed Student's t-test for each peptide by comparing the
two EAE with the two control values using Excel (Micro-
soft Corporation, Redmond, WA).
Western blotting analysis
Three independent control and EAE samples were used for
Western blotting analysis. Thirty micrograms of proteins
from each sample were first resolved on a 12.5% SDS-
PAGE gel and then transferred to a nitrocellulose mem-
brane (Bio-Rad, Hercules, CA, USA). The membrane was
rinsed with PBS and the non specific binding sites were
blocked in a solution of 5% nonfat milk in PBST (0.05%
Tween 20 in PBS) for 1 h at room temperature, followed
by three washes in PBST for 10 min each. The membrane
was first incubated with rabbit α2-M antibody (ab58703,
Abcam Inc. Cambridge, MA, USA) (1:1,000 dilution)
overnight and then washed in PBST buffer as described
above. The immunocomplexes were visualized by West-
ern Lightning® Western Blot Chemiluminescence Reagent
Plus (PerkinElmer, Waltham, MA, USA), using goat anti-
rabbit IgG coupled to horseradish peroxidase as the sec-
ondary antibody (170–6515, Bio-Rad, Hercules, CA,
USA). The membrane was stripped and re-probed with
either mouse anti-glyceraldehyde-3-phosphate dehydro-
genase (10R-G109A, Fitzgerald, Concord, MA, USA)
(1:10,000 dilution), or anti-neurofilament light polypep-
tide (sc-12980, Santa cruz biotechnology, Santa Cruz, CA,
USA) (1:500 dilution), or anti-β2-microgloblulin (sc-
69963, Santa cruz biotechnology, Santa Cruz, CA, USA)
(1:500 dilution) and or anti-sulfated glycoprotein 1
(ab68466, Abcam Inc. Cambridge, MA, USA) (1:1,000
dilution).
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EAE: experimental autoimmune encephalomyelitis;
iTRAQ: isobaric tags for relative and absolute quantifica-
tion.
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peak lists for the database search. Peptides identified with confidence 
interval values ≥ 99% are reported here.
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List of all the peptides identified for the proteins listed in Table 1. Pro-
teinPilot software (ABI) was used to process the tandem mass spectra and 
generate peak lists for the database search. Peptides identified with the 
confidence interval values ≥ 95% are reported here and were used for cal-
culation of the protein expression ratios.
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Additional file 3
MS/MS spectra of the semi-tryptic peptides listed in Table 1. All MS/
MS spectra were acquired on a 4700 MALDI TOF/TOF tandem MS 
instrument (ABI). The spectra were matched to proteins by ProteinPilot 
software (ABI).
Click here for file
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5956-7-25-S3.pdf]
Additional file 4
Amino acid sequence alignment of the α1 and α2 macroglobulins. The 
alignment was performed using ClustalW. Rat α1 and α2 macroglobulins 
showing ~56% of sequence homology.
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